Biotech

All Articles

AstraZeneca articles records on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early examine the efficiency of its own internal antibody-drug c...

iTeos- GSK's TIGIT superstar shows purposeful enhancement

.After announcing a phase 3 launch based upon good midstage end results, iTeos and also GSK are actu...

More collective FDA can easily speed up unusual ailment R&ampD: file

.The FDA needs to be extra open as well as collective to unleash a rise in approvals of rare ailment...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It is actually an unusually active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bi...

Atea's COVID antiviral neglects to halt hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually neglected another COVID-19 test, however the biotech s...

Neurocrine's proposal to spare schizophrenia possibility fails

.Neurocrine Biosciences' mental illness program pivot has failed. The biotech was unable to reproduc...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in an overdue access to the radioligand event, paying out one hundred m...

F 2G raises $100M for 2nd effort to obtain brand new antifungal to market

.After F2G's 1st effort to receive a brand-new class of antifungal to market was actually hindered b...

Moderna targets $1.1 B in R&ampD spending slices, falls 5 systems among productivity pressures

.Moderna has vowed to cut R&ampD spending through $1.1 billion through 2027. The decision to retract...

Sanofi's $80M bet on Fulcrum dystrophy medicine ends in phase 3 lose big

.Just four months after Sanofi wager $80 million in upfront cash money on Fulcrum Rehabs' losmapimod...